Dexilant (Dexlansoprazole) Patent Expiration, LOE Window & CMS Spending

Dexilant (Dexlansoprazole) by Takeda: FDA Orange Book LOE 2032-03-05, 4 AB generics, $63.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN022287 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-03-05
Orange Book Patents (*PED Extensions)12 patents (4 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$63.5M
2024 Medicare Part D Spend$41.0M
2024 Medicaid Spend$22.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.